CASE Statement in Support of Rep. Hudson’s Efforts to Protect Patients on Medicare Part D
FOR IMMEDIATE RELEASE May 31, 2018 Washington, D.C. — Consumer Action for a Strong Economy (CASE) President Matt Kandrach released the following...
FOR IMMEDIATE RELEASE May 31, 2018 Washington, D.C. — Consumer Action for a Strong Economy (CASE) President Matt Kandrach released the following...
As Congress continues to debate the best fixes for our healthcare system, our representatives in Washington have an opportunity to...
May 22, 2018 Last week, pharmaceutical manufacturer Amgen announced that a new drug treating migraines will cost less than analysts...
This week President Trump will unveil his plan to help bring down the cost of prescription drugs, helping fulfill his...
The Health Care Price Index rose by 2.2 percent from March 2017 to March 2018, the largest price increase since...
Matthew Kandrach – President, CASE April 3rd, 2018 – https://bit.ly/2q4a2UO Pharmacy Benefit Managers (PBMs) — health insurance middle-men wedged between plan...
If the makers of Coke or KFC’s famous fried chicken ever fear for keeping their recipes private and confidential, they...
Matthew Kandrach – President, CASE March 23, 2018 – https://bit.ly/2pzgoKC Americans typically view competition in the economy as a way to...
The infamous Medicare Part D ‘donut hole,’ which leaves seniors with a coverage gap for prescription drugs, has vexed Washington...
Matthew Kandrach – President, CASE February 26, 2018 – http://bit.ly/2BRIXLe The recently passed 600-page Bipartisan Budget Act of 2018 will impact...
.@POTUS’ IRA is driving up Part D premiums for millions of Medicare beneficiaries, yet Dems like @SenSanders continue to help tout this disastrous legislation. The Biden-Harris @WhiteHouse is misleading the public on their policy’s real impact.
Two weeks from election day, the supposedly independent @FCC is proposing price regulation of #broadband by restricting what data plans companies can offer.
By prohibiting usage-based plans, the FCC would end up increasing prices FOR EVERYONE, including low-data users!
CASE Letter Urges FDA & FTC to Scrutinize Deal Between L’Oréal and Galderma -- "Both companies are currently under investigation or facing sizable lawsuits from claims that they have used harmful chemicals in their products."
https://caseforconsumers.org/2024/10/21/case-letter-urges-fda-ftc-to-scrutinize-deal-between-loreal-and-galderma/
© 2025 · Case for Consumers